RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non–small cell lung cancer

K Nakagawa, E Nadal, EB Garon, M Nishio, T Seto… - Clinical Cancer …, 2021 - AACR
Purpose: In EGFR-mutated metastatic non–small cell lung cancer (NSCLC), outcomes from
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …
被引用次数：34 相关文章

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

K Nakagawa, E Nadal, EB Garon, M Nishio… - … Research, 2021, vol …, 2021 - diposit.ub.edu
Purpose: In E GFR-mutated metastatic non-small cell lung cancer (NSCLC), outcomes from
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer

K Nakagawa, E Nadal, EB Garon, M Nishio, T Seto… - 2021 - pubmed.ncbi.nlm.nih.gov
Purpose In EGFR-mutated metastatic non-small cell lung cancer (NSCLC), outcomes from
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …

RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non⇓ small cell lung cancer

K Nakagawa, E Nadal, EB Garon… - Clinical Cancer …, 2021 - mdanderson.elsevierpure.com
Purpose: In EGFR-mutated metastatic non–small cell lung cancer (NSCLC), outcomes from
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer

K Nakagawa, E Nadal, EB Garon… - CLINICAL CANCER …, 2021 - scholarworks.bwise.kr
Purpose: In E GFR-mutated metastatic non-small cell lung cancer (NSCLC), outcomes from
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …

RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.

K Nakagawa, E Nadal, EB Garon, M Nishio… - … Cancer Research: an …, 2021 - europepmc.org
Purpose In EGFR-mutated metastatic non-small cell lung cancer (NSCLC), outcomes from
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …
[HTML] nih.gov

[HTML][HTML] RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

K Nakagawa, E Nadal, EB Garon, M Nishio… - Clinical Cancer …, 2021 - ncbi.nlm.nih.gov
Purpose: In EGFR-mutated metastatic non–small cell lung cancer (NSCLC), outcomes from
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …